Sally Rodriguez

2.8k total citations · 2 hit papers
20 papers, 2.0k citations indexed

About

Sally Rodriguez is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Sally Rodriguez has authored 20 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 5 papers in Genetics and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Sally Rodriguez's work include Cystic Fibrosis Research Advances (14 papers), Neonatal Respiratory Health Research (3 papers) and Nematode management and characterization studies (2 papers). Sally Rodriguez is often cited by papers focused on Cystic Fibrosis Research Advances (14 papers), Neonatal Respiratory Health Research (3 papers) and Nematode management and characterization studies (2 papers). Sally Rodriguez collaborates with scholars based in United States, United Kingdom and Ireland. Sally Rodriguez's co-authors include Jane C. Davies, Claire Wainwright, Karl Yen, Claudia L. Ordoñez, J.S. Elborn, Michael W. Konstan, Elizabeth Tullis, Qunming Dong, Bonnie W. Ramsey and Isabelle Sermet‐Gaudelus and has published in prestigious journals such as New England Journal of Medicine, Blood and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Sally Rodriguez

19 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

2011 1.5k citations Bonnie W. Ramsey, Jane C. Davies et al. New England Journal of Medicine profile →
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

2013 369 citations Jane C. Davies, Claire Wainwright et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sally Rodriguez United States	6	1.8k	224	180	119	118	20	2.0k
Cori Daines United States	15	1.5k 0.9×	219 1.0×	202 1.1×	88 0.7×	58 0.5×	42	1.8k
Karl Yen United States	10	2.2k 1.2×	286 1.3×	586 3.3×	138 1.2×	113 1.0×	25	2.9k
Linda T. Wang United States	7	809 0.4×	97 0.4×	76 0.4×	81 0.7×	27 0.2×	14	1.0k
J. R. K. Savage United States	9	606 0.3×	235 1.0×	186 1.0×	59 0.5×	44 0.4×	19	895
Elizabeth Joseloff United States	14	689 0.4×	294 1.3×	93 0.5×	36 0.3×	21 0.2×	21	1.0k
Juliana Salazar Spain	23	285 0.2×	494 2.2×	73 0.4×	18 0.2×	59 0.5×	69	1.5k
Anthony Cahn United Kingdom	18	684 0.4×	226 1.0×	551 3.1×	11 0.1×	61 0.5×	61	1.3k
Zachary M. Sellers United States	19	274 0.2×	211 0.9×	53 0.3×	12 0.1×	191 1.6×	51	1.0k
Elizabeth A. Perkett United States	22	799 0.4×	327 1.5×	132 0.7×	12 0.1×	66 0.6×	36	1.2k
Mamta Muranjan India	15	87 0.0×	168 0.8×	149 0.8×	17 0.1×	136 1.2×	80	688

Countries citing papers authored by Sally Rodriguez

Since Specialization

Citations

This map shows the geographic impact of Sally Rodriguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Rodriguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Rodriguez more than expected).

Fields of papers citing papers by Sally Rodriguez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Rodriguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Rodriguez. The network helps show where Sally Rodriguez may publish in the future.

Co-authorship network of co-authors of Sally Rodriguez

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Rodriguez. A scholar is included among the top collaborators of Sally Rodriguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Rodriguez. Sally Rodriguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakhuda, Gary S., et al.. (2024). A pilot study to investigate the clinically predictive values of copy number variations detected by next-generation sequencing of cell-free deoxyribonucleic acid in spent culture media. Fertility and Sterility. 122(1). 42–51. 5 indexed citations

Kumar, Neha & Sally Rodriguez. (2018). Carrier Screening for Inherited Genetic Disorders: A Review of Current Practices. Elsevier eBooks. 63–75.

Flume, Patrick A., Claire Wainwright, D. Elizabeth Tullis, et al.. (2017). Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis. 17(1). 83–88. 37 indexed citations

Manoharan, Arun, Sally Rodriguez, Sara L. Bristow, et al.. (2017). Evaluating genetic ancestry and self-reported ethnicity in the context of carrier screening. BMC Genetics. 18(1). 99–99. 35 indexed citations

Rodriguez, Sally, et al.. (2016). 233: Non-invasive prenatal screening: is clinical practice going beyond the guidelines?. American Journal of Obstetrics and Gynecology. 216(1). S146–S147. 1 indexed citations

Rodriguez, Sally, Debra Roter, Carlos Castillo‐Salgado, Gillian W. Hooker, & Lori H. Erby. (2015). Translation and validation of a Spanish-language genetic health literacy screening tool.. Health Psychology. 34(2). 120–129. 11 indexed citations

Bristow, Sara L., et al.. (2015). How many carriers are you missing?: the value of expanded carrier screening. Fertility and Sterility. 104(3). e65–e66. 1 indexed citations

Konstan, Michael W., Barry J. Plant, J.S. Elborn, et al.. (2015). Efficacy response in CF patients treated with ivacaftor: Post-hoc analysis. Pediatric Pulmonology. 50(5). 447–455. 13 indexed citations

Solem, Caitlyn T., et al.. (2014). Responsiveness Of The Eq-5d Index And Visual Analog Scale To Changes In Lung Function In Patients With Cystic Fibrosis. Value in Health. 17(3). A178–A178. 4 indexed citations

10.

Rodriguez, Sally, Cristina Rodríguez de Miguel, Íngrid Ordás, et al.. (2014). P270 Capsule endoscopy (CE) is superior to magnetic resonance enterography (MRE) for the assessment of small bowel lesions in Crohn's disease (CD) patients: a comparative trial. Journal of Crohn s and Colitis. 8. S175–S176. 2 indexed citations

11.

Davies, Jane C., Claire Wainwright, Gerard J. Canny, et al.. (2013). Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation. American Journal of Respiratory and Critical Care Medicine. 187(11). 1219–1225. 369 indexed citations breakdown →

12.

Flume, Patrick A., et al.. (2013). 58 Pulmonary exacerbations in CF patients with the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis. 12. S63–S63. 3 indexed citations

13.

Elborn, J.S., Barry J. Plant, Michael W. Konstan, et al.. (2013). Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis. 42. 5059. 1 indexed citations

14.

Plant, Barry J., Michael W. Konstan, Sally Rodriguez, et al.. (2013). 53 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis. Journal of Cystic Fibrosis. 12. S62–S62. 2 indexed citations

15.

Elborn, J.S., Claire Wainwright, Isabelle Sermet‐Gaudelus, et al.. (2012). Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation. 40. 1840. 1 indexed citations

16.

Griese, Matthias, Bonnie W. Ramsey, Sally Rodriguez, Karl Yen, & J.S. Elborn. (2012). 44 Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation. Journal of Cystic Fibrosis. 11. S67–S67. 3 indexed citations

17.

McKone, Edward F., Sally Rodriguez, Karl Yen, & Jane C. Davies. (2012). Long-term safety and efficacy of ivacaftor in subjects with CF who have the G551D-CFTR mutation. 40. 1842. 1 indexed citations

18.

Plant, Barry J., Bonnie W. Ramsey, Karl Yen, et al.. (2011). Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation. European Respiratory Journal. 38(Suppl 55). 4655–4655. 1 indexed citations

19.

Ramsey, Bonnie W., Jane C. Davies, Noel G. McElvaney, et al.. (2011). A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. New England Journal of Medicine. 365(18). 1663–1672. 1528 indexed citations breakdown →

20.

Brenner, Louis, Paul Miller, Sally Rodriguez, Nainesh Parikh, & Daniel W. Coyne. (2007). Treatment of Iron-Deficiency Anemia with IV Ferumoxytol in CKD Patients: Efficacy Compared with Oral Iron across Different Age Groups.. Blood. 110(11). 2679–2679. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact